{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:33:56Z","timestamp":1792528436448,"version":"4.5.0"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA288236"],"award-info":[{"award-number":["R01CA288236"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite advances in therapy, survival rates for metastatic melanoma remain low. Drug-tolerant persister cells (persisters) can facilitate cancer recurrence, yet their characteristics and vulnerabilities differ across cancers and even within melanoma, depending on mutational context and treatment strategy. Both preexisting phenotypic traits and drug-induced adaptations contribute to persister formation, linked by \u201cprimed\u201d persisters that exhibit intermediate states observed in multiple studies. Compared with parental melanoma cells and other phenotypic variants such as melanoma stem cells or senescent cells, persisters show altered and reversible differentiation programs, distinct metabolic adaptations, and rewired signaling networks, all affected by the tumor microenvironment, but remain poorly understood. This review focuses on melanoma persisters, highlighting advances in understanding their origins, signaling plasticity, metabolic rewiring, and therapeutic vulnerabilities. By identifying gaps, this review further provides much-needed recommendations for future research and outlines priorities for advancing persister-directed interventions toward clinical translation.<\/jats:p>","DOI":"10.1038\/s42003-026-10143-w","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:54:46Z","timestamp":1777406086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasticity, signaling, and metabolic rewiring in melanoma persister cells"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4955-9596","authenticated-orcid":false,"given":"Shayne","family":"Sensenbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han G.","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8499-9154","authenticated-orcid":false,"given":"Mehmet A.","family":"Orman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"10143_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75, 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"key":"10143_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1001\/jamadermatol.2016.4512","volume":"153","author":"AM Glazer","year":"2017","unstructured":"Glazer, A. M., Winkelmann, R. R., Farberg, A. S. & Rigel, D. S. Analysis of trends in US melanoma incidence and mortality. JAMA Dermatol. 153, 225\u2013226 (2017).","journal-title":"JAMA Dermatol."},{"key":"10143_CR3","doi-asserted-by":"crossref","unstructured":"Koolen, P. G. L. et al. Recurrence rates over 20 years in the treatment of malignant melanoma: immediate versus delayed reconstruction. Plast. Reconstr. Surg. Glob. Open 5, e1378 (2017).","DOI":"10.1097\/GOX.0000000000001378"},{"key":"10143_CR4","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949\u2013954 (2002).","journal-title":"Nature"},{"key":"10143_CR5","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1038\/sj.onc.1207780","volume":"23","author":"M Daniotti","year":"2004","unstructured":"Daniotti, M. et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 5968\u20135977 (2004).","journal-title":"Oncogene"},{"key":"10143_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/ITT.S134842","volume":"7","author":"B Domingues","year":"2018","unstructured":"Domingues, B., Lopes, J. M., Soares, P. & P\u00f3pulo, H. Melanoma treatment in review. Immunotargets Ther. 7, 35\u201349 (2018).","journal-title":"Immunotargets Ther."},{"key":"10143_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.21037\/atm.2016.06.07","volume":"4","author":"JL Manzano","year":"2016","unstructured":"Manzano, J. L. et al. Resistant mechanisms to BRAF inhibitors in melanoma. Ann. Transl. Med. 4, 237 (2016).","journal-title":"Ann. Transl. Med."},{"key":"10143_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.21037\/atm.2017.06.09","volume":"5","author":"I Arozarena","year":"2017","unstructured":"Arozarena, I. & Wellbrock, C. Overcoming resistance to BRAF inhibitors. Ann. Transl. Med. 5, 387 (2017).","journal-title":"Ann. Transl. Med."},{"key":"10143_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(00)74210-3","volume":"244","author":"JW Bigger","year":"1944","unstructured":"Bigger, J. W. Treatment of staphylococcal infections with penicillin by intermittent sterilisation.  Lancet 244, 497\u2013500 (1944).","journal-title":"Lancet"},{"key":"10143_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3181\/00379727-50-13773","volume":"50","author":"GL Hobby","year":"1942","unstructured":"Hobby, G. L., Meyer, K. & Chaffee, E. Observations on the mechanism of action of penicillin. Exp. Biol. Med. 50, 281\u2013285 (1942).","journal-title":"Exp. Biol. Med."},{"key":"10143_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69\u201380 (2010).","journal-title":"Cell"},{"key":"10143_CR12","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247\u2013250 (2017).","journal-title":"Nature"},{"key":"10143_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10690","volume":"7","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat. Commun. 7, 10690 (2016).","journal-title":"Nat. Commun."},{"key":"10143_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.08.003","volume":"21\u201322","author":"S Blatter","year":"2015","unstructured":"Blatter, S. & Rottenberg, S. Minimal residual disease in cancer therapy\u2014small things make all the difference. Drug Resist. Updates 21\u201322, 1\u201310 (2015).","journal-title":"Drug Resist. Updates"},{"key":"10143_CR15","doi-asserted-by":"crossref","unstructured":"Travnickova, J. et al. Fate mapping melanoma persister cells through regression and into recurrent disease in adult zebrafish. DMM Disease Models Mech. 15, dmm049566 (2022).","DOI":"10.1242\/dmm.049566"},{"key":"10143_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/nm.3984","volume":"22","author":"N Andor","year":"2015","unstructured":"Andor, N. et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat. Med. 22, 105\u2013113 (2015).","journal-title":"Nat. Med."},{"key":"10143_CR17","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/exd.13002","volume":"25","author":"SJ Hachey","year":"2016","unstructured":"Hachey, S. J. & Boiko, A. D. Therapeutic implications of melanoma heterogeneity. Exp. Dermatol. 25, 497\u2013500 (2016).","journal-title":"Exp. Dermatol."},{"key":"10143_CR18","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1101\/gad.329771.119","volume":"33","author":"F Rambow","year":"2019","unstructured":"Rambow, F., Marine, J. C. & Goding, C. R. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 33, 1295\u20131318 (2019).","journal-title":"Genes Dev."},{"key":"10143_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf, D. et al. Melanoma.  Lancet 392, 971\u2013984 (2018).","journal-title":"Lancet"},{"key":"10143_CR20","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis, L. E., Shalin, S. C. & Tackett, A. J. Current state of melanoma diagnosis and treatment. Cancer Biol. Ther. 20, 1366\u20131379 (2019).","journal-title":"Cancer Biol. Ther."},{"key":"10143_CR21","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1002\/jcp.25019","volume":"230","author":"A Marzuka","year":"2015","unstructured":"Marzuka, A., Huang, L., Theodosakis, N. & Bosenberg, M. Melanoma treatments: advances and mechanisms. J. Cell. Physiol. 230, 2626\u20132633 (2015).","journal-title":"J. Cell. Physiol."},{"key":"10143_CR22","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1158\/0008-5472.CAN-21-3844","volume":"82","author":"PK Dhanyamraju","year":"2022","unstructured":"Dhanyamraju, P. K., Schell, T. D., Amin, S. & Robertson, G. P. Drug-tolerant persister cells in cancer therapy resistance. Cancer Res. 82, 2503\u20132514 (2022).","journal-title":"Cancer Res."},{"key":"10143_CR23","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","volume":"16","author":"M Mikubo","year":"2021","unstructured":"Mikubo, M., Inoue, Y., Liu, G. & Tsao, M. S. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. J. Thorac. Oncol. 16, 1798\u20131809 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"10143_CR24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.3390\/cancers13051118","volume":"13","author":"G De Conti","year":"2021","unstructured":"De Conti, G., Dias, M. H. & Bernards, R. Fighting drug resistance through the targeting of drug-tolerant persister cells. Cancers 13, 1118 (2021).","journal-title":"Cancers"},{"key":"10143_CR25","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.3390\/cells9122601","volume":"9","author":"M Swayden","year":"2020","unstructured":"Swayden, M., Chhouri, H., Anouar, Y. & Grumolato, L. Tolerant\/persister cancer cells and the path to resistance to targeted therapy. Cells 9, 2601 (2020).","journal-title":"Cells"},{"key":"10143_CR26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu, Y. et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat. Rev. Clin. Oncol. 20, 799\u2013813 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10143_CR27","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","volume":"183","author":"S Shen","year":"2020","unstructured":"Shen, S., Vagner, S. & Robert, C. Persistent cancer cells: the deadly survivors. Cell 183, 860\u2013874 (2020).","journal-title":"Cell"},{"key":"10143_CR28","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","volume":"24","author":"M Russo","year":"2024","unstructured":"Russo, M. et al. Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. Nat. Rev. Cancer 24, 694\u2013717 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"10143_CR29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.molcel.2021.12.001","volume":"82","author":"R Rodriguez","year":"2022","unstructured":"Rodriguez, R., Schreiber, S. L. & Conrad, M. Persister cancer cells: iron addiction and vulnerability to ferroptosis. Mol. Cell 82, 728\u2013740 (2022).","journal-title":"Mol. Cell"},{"key":"10143_CR30","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/cancers13112666","volume":"13","author":"HF Cabanos","year":"2021","unstructured":"Cabanos, H. F. & Hata, A. N. Emerging insights into targeted therapy-tolerant persister cells in cancer. Cancers 13, 2666 (2021).","journal-title":"Cancers"},{"key":"10143_CR31","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.cels.2020.10.002","volume":"11","author":"L Gerosa","year":"2020","unstructured":"Gerosa, L. et al. Receptor-driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells. Cell Syst. 11, 478\u2013494.e9 (2020).","journal-title":"Cell Syst."},{"key":"10143_CR32","doi-asserted-by":"publisher","first-page":"112570","DOI":"10.1016\/j.celrep.2023.112570","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim, S., Carvajal, R., Kim, M. & Yang, H. W. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF\/MEK inhibition in melanoma. Cell Rep. 42, 112570 (2023).","journal-title":"Cell Rep."},{"key":"10143_CR33","doi-asserted-by":"publisher","first-page":"780192","DOI":"10.3389\/fmolb.2021.780192","volume":"8","author":"P Karki","year":"2022","unstructured":"Karki, P., Angardi, V., Mier, J. C. & Orman, M. A. A transient metabolic state in melanoma persister cells mediated by chemotherapeutic treatments. Front. Mol. Biosci. 8, 780192 (2022).","journal-title":"Front. Mol. Biosci."},{"key":"10143_CR34","doi-asserted-by":"crossref","unstructured":"Fallahi-Sichani, M. et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol. Syst. Biol. 13, 905 (2017).","DOI":"10.15252\/msb.20166796"},{"key":"10143_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-30641-9","volume":"13","author":"H Chauvistr\u00e9","year":"2022","unstructured":"Chauvistr\u00e9, H. et al. Persister state-directed transitioning and vulnerability in melanoma. Nat. Commun. 13, 1\u201317 (2022).","journal-title":"Nat. Commun."},{"key":"10143_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-13360-6","volume":"10","author":"S Shen","year":"2019","unstructured":"Shen, S. et al. An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells. Nat. Commun. 10, 1\u201314 (2019).","journal-title":"Nat. Commun."},{"key":"10143_CR37","doi-asserted-by":"crossref","unstructured":"Chen, M. et al. Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapse. Cell Rep. Med. 5, 101471 (2024).","DOI":"10.1016\/j.xcrm.2024.101471"},{"key":"10143_CR38","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","volume":"596","author":"Y Oren","year":"2021","unstructured":"Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576\u2013582 (2021).","journal-title":"Nature"},{"key":"10143_CR39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431\u2013435 (2017).","journal-title":"Nature"},{"key":"10143_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.ccr.2013.05.003","volume":"23","author":"A Roesch","year":"2013","unstructured":"Roesch, A. et al. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells. Cancer Cell 23, 811\u2013825 (2013).","journal-title":"Cancer Cell"},{"key":"10143_CR41","doi-asserted-by":"crossref","unstructured":"Gautron, A. et al. CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and resistance. EMBO Mol. Med. 13, e13466 (2021).","DOI":"10.15252\/emmm.202013466"},{"key":"10143_CR42","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-22-1826","volume":"83","author":"OM Eichhoff","year":"2023","unstructured":"Eichhoff, O. M. et al. ROS induction targets persister cancer cells with low metabolic activity in NRAS-mutated melanoma. Cancer Res. 83, 1128\u20131146 (2023).","journal-title":"Cancer Res."},{"key":"10143_CR43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ccell.2021.05.015","volume":"39","author":"O Marin-Bejar","year":"2021","unstructured":"Marin-Bejar, O. et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell 39, 1135\u20131149.e8 (2021).","journal-title":"Cancer Cell"},{"key":"10143_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/metabo11110777","volume":"11","author":"P Karki","year":"2021","unstructured":"Karki, P., Sensenbach, S., Angardi, V. & Orman, M. A. Braf-inhibitor-induced metabolic alterations in a375 melanoma cells. Metabolites 11, 777 (2021).","journal-title":"Metabolites"},{"key":"10143_CR45","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue, T. & Weinberg, R. A. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 14, 611\u2013629 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10143_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-06951-2","volume":"9","author":"S Corre","year":"2018","unstructured":"Corre, S. et al. Sustained activation of the aryl hydrocarbon receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma. Nat. Commun. 9, 1\u201313 (2018).","journal-title":"Nat. Commun."},{"key":"10143_CR47","doi-asserted-by":"publisher","first-page":"1368711","DOI":"10.3389\/fcell.2024.1368711","volume":"12","author":"D Tchelougou","year":"2024","unstructured":"Tchelougou, D. et al. Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells. Front. Cell Dev. Biol. 12, 1368711 (2024).","journal-title":"Front. Cell Dev. Biol."},{"key":"10143_CR48","doi-asserted-by":"publisher","first-page":"e003863","DOI":"10.1136\/jitc-2021-003863","volume":"10","author":"B Thier","year":"2022","unstructured":"Thier, B. et al. Innate immune receptor signaling induces transient melanoma dedifferentiation while preserving immunogenicity. J. Immunother. Cancer 10, e003863 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"10143_CR49","doi-asserted-by":"publisher","unstructured":"Hayford, C. E. et al. A heterogeneous drug tolerant persister state in BRAF-mutant melanoma is characterized by ion channel dysregulation and susceptibility to ferroptosis. bioRxiv https:\/\/doi.org\/10.1101\/2022.02.03.479045 (2022).","DOI":"10.1101\/2022.02.03.479045"},{"key":"10143_CR50","doi-asserted-by":"crossref","unstructured":"Nokin, M. J. et al. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell Rep. Med. 5, 101663 (2024).","DOI":"10.1016\/j.xcrm.2024.101663"},{"key":"10143_CR51","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1158\/0008-5472.CAN-23-1006","volume":"83","author":"E Griessinger","year":"2023","unstructured":"Griessinger, E. et al. Oxidative phosphorylation fueled by fatty acid oxidation sensitizes leukemic stem cells to cold. Cancer Res. 83, 2461\u20132470 (2023).","journal-title":"Cancer Res."},{"key":"10143_CR52","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.2337\/db11-1437","volume":"61","author":"MG Rosca","year":"2012","unstructured":"Rosca, M. G. et al. Oxidation of fatty acids is the source of increased mitochondrial reactive oxygen species production in kidney cortical tubules in early diabetes. Diabetes 61, 2074\u20132083 (2012).","journal-title":"Diabetes"},{"key":"10143_CR53","doi-asserted-by":"publisher","first-page":"108421","DOI":"10.1016\/j.celrep.2020.108421","volume":"33","author":"S Shen","year":"2020","unstructured":"Shen, S. et al. Melanoma persister cells are tolerant to BRAF\/MEK inhibitors via ACOX1-mediated fatty acid oxidation. Cell Rep. 33, 108421 (2020).","journal-title":"Cell Rep."},{"key":"10143_CR54","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1158\/0008-5472.CAN-24-0690","volume":"85","author":"JC Rubinstein","year":"2025","unstructured":"Rubinstein, J. C. et al. Spatiotemporal profiling defines persistence and resistance dynamics during targeted treatment of melanoma. Cancer Res. 85, 987\u20131002 (2025).","journal-title":"Cancer Res."},{"key":"10143_CR55","doi-asserted-by":"publisher","first-page":"31776","DOI":"10.1021\/acsomega.5c02807","volume":"10","author":"S Sensenbach","year":"2025","unstructured":"Sensenbach, S. et al. The role of c-Jun signaling in cytidine analog-induced cell death in melanoma. ACS Omega 10, 31776\u201331788 (2025).","journal-title":"ACS Omega"},{"key":"10143_CR56","doi-asserted-by":"crossref","unstructured":"Huang, F. et al. Peroxisome disruption alters lipid metabolism and potentiates antitumor response with MAPK-targeted therapy in melanoma. J. Clin. Invest. 133, e166644 (2023).","DOI":"10.1172\/JCI166644"},{"key":"10143_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.007","volume":"187","author":"AM Kidger","year":"2018","unstructured":"Kidger, A. M., Sipthorp, J. & Cook, S. J. ERK1\/2 inhibitors: new weapons to inhibit the RAS-regulated RAF-MEK1\/2-ERK1\/2 pathway. Pharmacol. Ther. 187, 45\u201360 (2018).","journal-title":"Pharmacol. Ther."},{"key":"10143_CR58","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1158\/2159-8290.CD-23-1161","volume":"14","author":"D Rosano","year":"2024","unstructured":"Rosano, D. et al. Long-term multimodal recording reveals epigenetic adaptation routes in dormant breast cancer cells. Cancer Discov. 14, 866\u2013889 (2024).","journal-title":"Cancer Discov."},{"key":"10143_CR59","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s44321-024-00088-0","volume":"16","author":"M Momeny","year":"2024","unstructured":"Momeny, M. et al. DUSP6 inhibition overcomes neuregulin\/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO Mol. Med. 16, 1603\u20131629 (2024).","journal-title":"EMBO Mol. Med."},{"key":"10143_CR60","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890\u2013904.e5 (2018).","journal-title":"Cancer Cell"},{"key":"10143_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21549-x","volume":"12","author":"C Yang","year":"2021","unstructured":"Yang, C., Tian, C., Hoffman, T. E., Jacobsen, N. K. & Spencer, S. L. Melanoma subpopulations that rapidly escape MAPK pathway inhibition incur DNA damage and rely on stress signalling. Nat. Commun. 12, 1747 (2021).","journal-title":"Nat. Commun."},{"key":"10143_CR62","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843\u2013855.e19 (2018).","journal-title":"Cell"},{"key":"10143_CR63","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton, T. et al. Identification of cells initiating human melanomas. Nature 451, 345\u2013349 (2008).","journal-title":"Nature"},{"key":"10143_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31536-5","volume":"13","author":"Q Guo","year":"2022","unstructured":"Guo, Q. et al. Clonal barcoding with qPCR detection enables live cell functional analyses for cancer research. Nat. Commun. 13, 3837 (2022).","journal-title":"Nat. Commun."},{"key":"10143_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-02085-1","volume":"21","author":"CE Eyler","year":"2020","unstructured":"Eyler, C. E. et al. Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance. Genome Biol. 21, 174 (2020).","journal-title":"Genome Biol."},{"key":"10143_CR66","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.trecan.2023.03.008","volume":"9","author":"KK Howland","year":"2023","unstructured":"Howland, K. K. & Brock, A. Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions. Trends Cancer 9, 591\u2013601 (2023).","journal-title":"Trends Cancer"},{"key":"10143_CR67","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","volume":"141","author":"A Roesch","year":"2010","unstructured":"Roesch, A. et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583\u2013594 (2010).","journal-title":"Cell"},{"key":"10143_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-025-02336-2","volume":"23","author":"O Knowles","year":"2025","unstructured":"Knowles, O. et al. A CD24+CD271+ melanoma cancer stem cell possesses hybrid characteristics of its single marker counterparts and promotes invasion and therapeutic resistance. BMC Biol. 23, 235 (2025).","journal-title":"BMC Biol."},{"key":"10143_CR69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nature10600","volume":"479","author":"DJ Baker","year":"2011","unstructured":"Baker, D. J. et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479, 232\u2013236 (2011).","journal-title":"Nature"},{"key":"10143_CR70","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1101\/gad.17276711","volume":"25","author":"Y Chien","year":"2011","unstructured":"Chien, Y. et al. Control of the senescence-associated secretory phenotype by NF-\u03baB promotes senescence and enhances chemosensitivity. Genes Dev. 25, 2125\u20132136 (2011).","journal-title":"Genes Dev."},{"key":"10143_CR71","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cell.2013.08.062","volume":"155","author":"SL Spencer","year":"2013","unstructured":"Spencer, S. L. et al. The proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit. Cell 155, 369\u2013383 (2013).","journal-title":"Cell"},{"key":"10143_CR72","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.cell.2007.12.033","volume":"132","author":"A Sakaue-Sawano","year":"2008","unstructured":"Sakaue-Sawano, A. et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487\u2013498 (2008).","journal-title":"Cell"},{"key":"10143_CR73","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3390\/cancers12102870","volume":"12","author":"I Falcone","year":"2020","unstructured":"Falcone, I. et al. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. Cancers (Basel). 12, 2870 (2020).","journal-title":"Cancers (Basel)."},{"key":"10143_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13402-024-00969-z","volume":"48","author":"S Peppicelli","year":"2025","unstructured":"Peppicelli, S. et al. Acidity and hypoxia of tumor microenvironment, a positive interplay in extracellular vesicle release by tumor cells. Cell. Oncol. 48, 27\u201341 (2025).","journal-title":"Cell. Oncol."},{"key":"10143_CR75","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/hmg\/ddae056","volume":"33","author":"Q Zhou","year":"2024","unstructured":"Zhou, Q. et al. Melanoma-associated fibroblasts in tumor-promotion flammation and antitumor immunity: novel mechanisms and potential immunotherapeutic strategies. Hum. Mol. Genet. 33, 1186\u20131193 (2024).","journal-title":"Hum. Mol. Genet."},{"key":"10143_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66376-6","volume":"16","author":"Z Wang","year":"2025","unstructured":"Wang, Z. et al. Drug-tolerant persister cells in cancer: bridging the gaps between bench and bedside. Nat. Commun. 16, 10048 (2025).","journal-title":"Nat. Commun."},{"key":"10143_CR77","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20160855","volume":"214","author":"HL Young","year":"2017","unstructured":"Young, H. L. et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. J. Exp. Med. 214, 1691\u20131710 (2017).","journal-title":"J. Exp. Med."},{"key":"10143_CR78","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1158\/0008-5472.CAN-19-2914","volume":"80","author":"CA Girard","year":"2020","unstructured":"Girard, C. A. et al. A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma. Cancer Res. 80, 1927\u20131941 (2020).","journal-title":"Cancer Res."},{"key":"10143_CR79","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41392-019-0100-7","volume":"4","author":"T Liu","year":"2019","unstructured":"Liu, T. et al. The \u03b2-catenin\/YAP signaling axis is a key regulator of melanoma-associated fibroblasts. Signal Transduct. Target. Ther. 4, 63 (2019).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10143_CR80","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1038\/onc.2014.372","volume":"34","author":"D Ravindran Menon","year":"2015","unstructured":"Ravindran Menon, D. et al. A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene 34, 4448\u20134459 (2015).","journal-title":"Oncogene"},{"key":"10143_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.canlet.2012.04.025","volume":"324","author":"G Comito","year":"2012","unstructured":"Comito, G. et al. Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. Cancer Lett. 324, 31\u201341 (2012).","journal-title":"Cancer Lett."},{"key":"10143_CR82","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/embj.201592081","volume":"35","author":"MH Kim","year":"2016","unstructured":"Kim, M. H. et al. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation. EMBO J. 35, 462\u2013478 (2016).","journal-title":"EMBO J."},{"key":"10143_CR83","doi-asserted-by":"crossref","unstructured":"Ziani, L., Buart, S., Chouaib, S. & Thiery, J. Hypoxia increases melanoma-associated fibroblasts immunosuppressive potential and inhibitory effect on T cell-mediated cytotoxicity. Oncoimmunology 10, 1950953 (2021).","DOI":"10.1080\/2162402X.2021.1950953"},{"key":"10143_CR84","doi-asserted-by":"publisher","first-page":"6697","DOI":"10.4049\/jimmunol.0800997","volume":"182","author":"CM Bucks","year":"2009","unstructured":"Bucks, C. M., Norton, J. A., Boesteanu, A. C., Mueller, Y. M. & Katsikis, P. D. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion.  J. Immunol. 182, 6697\u20136708 (2009).","journal-title":"J. Immunol."},{"key":"10143_CR85","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch, L. et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Investig. 121, 2350\u20132360 (2011).","journal-title":"J. Clin. Investig."},{"key":"10143_CR86","doi-asserted-by":"crossref","unstructured":"Hutter-Karakoc, I. et al. Chronic antigen stimulation in melanoma induces T cell exhaustion and limits efficacy of T cell bispecific therapies. Oncoimmunology 14, 2526444 (2025).","DOI":"10.1080\/2162402X.2025.2526444"},{"key":"10143_CR87","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","volume":"120","author":"C Groth","year":"2019","unstructured":"Groth, C. et al. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br. J. Cancer 120, 16\u201325 (2019).","journal-title":"Br. J. Cancer"},{"key":"10143_CR88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen, S. et al. Macrophages in immunoregulation and therapeutics. Signal Transduct. Target. Ther. 8, 207 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10143_CR89","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.3390\/cancers13246173","volume":"13","author":"U \u00c7ak\u0131r","year":"2021","unstructured":"\u00c7ak\u0131r, U. et al. Mesenchymal-stromal cell-like melanoma-associated fibroblasts increase IL-10 production by macrophages in a cyclooxygenase\/indoleamine 2,3-dioxygenase-dependent manner. Cancers (Basel). 13, 6173 (2021).","journal-title":"Cancers (Basel)."},{"key":"10143_CR90","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-22-2841","volume":"83","author":"D Kim","year":"2023","unstructured":"Kim, D. et al. Ccr2+ monocyte-derived macrophages influence trajectories of acquired therapy resistance in Braf-mutant melanoma. Cancer Res. 83, 2328\u20132344 (2023).","journal-title":"Cancer Res."},{"key":"10143_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-017-1347-9","volume":"15","author":"J-V Gaustad","year":"2017","unstructured":"Gaustad, J.-V., Simonsen, T. G., Andersen, L. M. K. & Rofstad, E. K. Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts. J. Transl. Med. 15, 241 (2017).","journal-title":"J. Transl. Med."},{"key":"10143_CR92","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Han, F., Du, Y., Shi, H. & Zhou, W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 8, 70 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10143_CR93","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1582-4934.2009.00994.x","volume":"14","author":"J Chiche","year":"2010","unstructured":"Chiche, J., Brahimi-Horn, M. C. & Pouyss\u00e9gur, J. Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 14, 771\u2013794 (2010).","journal-title":"J. Cell. Mol. Med."},{"key":"10143_CR94","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tcb.2017.10.006","volume":"28","author":"L Schito","year":"2018","unstructured":"Schito, L. & Rey, S. Cell-autonomous metabolic reprogramming in hypoxia. Trends Cell Biol. 28, 128\u2013142 (2018).","journal-title":"Trends Cell Biol."},{"key":"10143_CR95","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1158\/1535-7163.MCT-15-0963","volume":"15","author":"Y Qin","year":"2016","unstructured":"Qin, Y. et al. Hypoxia-driven mechanism of vemurafenib resistance in melanoma. Mol. Cancer Ther. 15, 2442\u20132454 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"10143_CR96","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/pcmr.12811","volume":"33","author":"I B\u00f6hme","year":"2020","unstructured":"B\u00f6hme, I. & Bosserhoff, A. Extracellular acidosis triggers a senescence-like phenotype in human melanoma cells. Pigment Cell Melanoma Res. 33, 41\u201351 (2020).","journal-title":"Pigment Cell Melanoma Res."},{"key":"10143_CR97","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.3390\/ijms24076122","volume":"24","author":"M Venturella","year":"2023","unstructured":"Venturella, M. et al. CA-IX-expressing small extracellular vesicles (sEVs) are released by melanoma cells under hypoxia and in the blood of advanced melanoma patients. Int. J. Mol. Sci. 24, 6122 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"10143_CR98","doi-asserted-by":"publisher","first-page":"34211","DOI":"10.1074\/jbc.M109.041152","volume":"284","author":"I Parolini","year":"2009","unstructured":"Parolini, I. et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J. Biol. Chem. 284, 34211\u201334222 (2009).","journal-title":"J. Biol. Chem."},{"key":"10143_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50848-z","volume":"9","author":"LNS Andrade","year":"2019","unstructured":"Andrade, L. N. S. et al. Extracellular vesicles shedding promotes melanoma growth in response to chemotherapy. Sci. Rep. 9, 14482 (2019).","journal-title":"Sci. Rep."},{"key":"10143_CR100","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1158\/0008-5472.CAN-19-0053","volume":"79","author":"V Fleming","year":"2019","unstructured":"Fleming, V. et al. Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715\u20134728 (2019).","journal-title":"Cancer Res."},{"key":"10143_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51778-6","volume":"9","author":"M Harmati","year":"2019","unstructured":"Harmati, M. et al. Small extracellular vesicles convey the stress-induced adaptive responses of melanoma cells. Sci. Rep. 9, 15329 (2019).","journal-title":"Sci. Rep."},{"key":"10143_CR102","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s42003-021-01954-0","volume":"4","author":"AC Gilmore","year":"2021","unstructured":"Gilmore, A. C. et al. An in vitro tumorigenesis model based on live-cell-generated oxygen and nutrient gradients. Commun. Biol. 4, 477 (2021).","journal-title":"Commun. Biol."},{"key":"10143_CR103","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.1158\/0008-5472.CAN-07-6387","volume":"68","author":"LI Ca\u0301rdenas-Navia","year":"2008","unstructured":"Ca\u0301rdenas-Navia, L. I. et al. The pervasive presence of fluctuating oxygenation in tumors. Cancer Res. 68, 5812\u20135819 (2008).","journal-title":"Cancer Res."},{"key":"10143_CR104","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","volume":"78","author":"JA Gallaher","year":"2018","unstructured":"Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. A. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 78, 2127\u20132139 (2018).","journal-title":"Cancer Res."},{"key":"10143_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53374-3","volume":"15","author":"S Shafighi","year":"2024","unstructured":"Shafighi, S. et al. Integrative spatial and genomic analysis of tumor heterogeneity with Tumoroscope. Nat. Commun. 15, 9343 (2024).","journal-title":"Nat. Commun."},{"key":"10143_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11738-0","volume":"10","author":"Z Xiao","year":"2019","unstructured":"Xiao, Z., Dai, Z. & Locasale, J. W. Metabolic landscape of the tumor microenvironment at single cell resolution. Nat. Commun. 10, 3763 (2019).","journal-title":"Nat. Commun."},{"key":"10143_CR107","doi-asserted-by":"publisher","first-page":"105389","DOI":"10.1016\/j.ebiom.2024.105389","volume":"109","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Single cell atlas reveals multilayered metabolic heterogeneity across tumour types. EBioMedicine 109, 105389 (2024).","journal-title":"EBioMedicine"},{"key":"10143_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34877-3","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nat. Commun. 13, 7250 (2022).","journal-title":"Nat. Commun."},{"key":"10143_CR109","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.ccell.2021.05.005","volume":"39","author":"KP Simeonov","year":"2021","unstructured":"Simeonov, K. P. et al. Single-cell lineage tracing of metastatic cancer reveals selection of hybrid EMT states. Cancer Cell 39, 1150\u20131162.e9 (2021).","journal-title":"Cancer Cell"},{"key":"10143_CR110","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1101\/gr.278944.124","volume":"34","author":"X Zhang","year":"2024","unstructured":"Zhang, X., Huang, Y., Yang, Y., Wang, Q.-E. & Li, L. Advancements in prospective single-cell lineage barcoding and their applications in research. Genome Res. 34, 2147\u20132162 (2024).","journal-title":"Genome Res."},{"key":"10143_CR111","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-022-00527-5","volume":"23","author":"D Entenberg","year":"2023","unstructured":"Entenberg, D., Oktay, M. H. & Condeelis, J. S. Intravital imaging to study cancer progression and metastasis. Nat. Rev. Cancer 23, 25\u201342 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"10143_CR112","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2397","volume":"8","author":"MW Dewhirst","year":"2008","unstructured":"Dewhirst, M. W., Cao, Y. & Moeller, B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat. Rev. Cancer 8, 425\u2013437 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"10143_CR113","first-page":"105","volume":"1805","author":"A Marusyk","year":"2010","unstructured":"Marusyk, A. & Polyak, K. Tumor heterogeneity: Causes and consequences. Biochim. Biophys. Acta 1805, 105\u2013117 (2010).","journal-title":"Biochim. Biophys. Acta"},{"key":"10143_CR114","doi-asserted-by":"publisher","first-page":"109010","DOI":"10.1016\/j.compchemeng.2025.109010","volume":"195","author":"G Singh","year":"2025","unstructured":"Singh, G. et al. Systematic design of pulse dosing to eradicate persister bacteria: the case of fluoroquinolones. Comput. Chem. Eng. 195, 109010 (2025).","journal-title":"Comput. Chem. Eng."},{"key":"10143_CR115","doi-asserted-by":"publisher","first-page":"e1010243","DOI":"10.1371\/journal.pcbi.1010243","volume":"19","author":"G Singh","year":"2023","unstructured":"Singh, G., Orman, M. A., Conrad, J. C. & Nikolaou, M. Systematic design of pulse dosing to eradicate persister bacteria. PLoS Comput. Biol. 19, e1010243 (2023).","journal-title":"PLoS Comput. Biol."},{"key":"10143_CR116","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26572-6","volume":"12","author":"M Gonzalez-Cao","year":"2021","unstructured":"Gonzalez-Cao, M. et al. Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial. Nat. Commun. 12, 7008 (2021).","journal-title":"Nat. Commun."},{"key":"10143_CR117","doi-asserted-by":"publisher","first-page":"113455","DOI":"10.1016\/j.ejca.2023.113455","volume":"196","author":"A Dayimu","year":"2024","unstructured":"Dayimu, A. et al. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). Eur. J. Cancer 196, 113455 (2024).","journal-title":"Eur. J. Cancer"},{"key":"10143_CR118","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"10143_CR119","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1200\/JCO.2015.62.0500","volume":"33","author":"DH Lawson","year":"2015","unstructured":"Lawson, D. H. et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and\/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group\u2013American College of Radiology Imaging Network Cancer Research Group (E4697). J. Clin. Oncol. 33, 4066\u20134076 (2015).","journal-title":"J. Clin. Oncol."},{"key":"10143_CR120","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3892\/ol.2021.12827","volume":"22","author":"Q Yin","year":"2021","unstructured":"Yin, Q., Shi, X., Lan, S., Jin, H. & Wu, D. Effect of melanoma stem cells on melanoma metastasis. Oncol. Lett. 22, 566 (2021).","journal-title":"Oncol. Lett."},{"key":"10143_CR121","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1200\/JCO.2007.15.5465","volume":"26","author":"SE Zabierowski","year":"2008","unstructured":"Zabierowski, S. E. & Herlyn, M. Melanoma stem cells: the dark seed of melanoma. J. Clin. Oncol. 26, 2890\u20132894 (2008).","journal-title":"J. Clin. Oncol."},{"key":"10143_CR122","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/febs.16021","volume":"289","author":"D Pedri","year":"2022","unstructured":"Pedri, D., Karras, P., Landeloos, E., Marine, J. & Rambow, F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 289, 1352\u20131368 (2022).","journal-title":"FEBS J."},{"key":"10143_CR123","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03278-5","volume":"24","author":"K Singvogel","year":"2024","unstructured":"Singvogel, K. & Schittek, B. Dormancy of cutaneous melanoma. Cancer Cell Int. 24, 88 (2024).","journal-title":"Cancer Cell Int."},{"key":"10143_CR124","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2019.10.005","volume":"179","author":"V Gorgoulis","year":"2019","unstructured":"Gorgoulis, V. et al. Cellular senescence: defining a path forward. Cell 179, 813\u2013827 (2019).","journal-title":"Cell"},{"key":"10143_CR125","doi-asserted-by":"crossref","unstructured":"Constantinou, S. M. & Bennett, D. C. Cell senescence and the genetics of melanoma development. Genes Chromosomes Cancer 63, e23273 (2024).","DOI":"10.1002\/gcc.23273"},{"key":"10143_CR126","doi-asserted-by":"publisher","first-page":"165965","DOI":"10.1016\/j.bbadis.2020.165965","volume":"1867","author":"AM Urbano","year":"2021","unstructured":"Urbano, A. M. Otto Warburg: The journey towards the seminal discovery of tumor cell bioenergetic reprogramming. Biochim. Biophys. Acta 1867, 165965 (2021).","journal-title":"Biochim. Biophys. Acta"},{"key":"10143_CR127","first-page":"309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science (1979) 123, 309\u2013314 (1956).","journal-title":"Science (1979)"},{"key":"10143_CR128","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","volume":"8","author":"O Warburg","year":"1927","unstructured":"Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519\u2013530 (1927).","journal-title":"J. Gen. Physiol."},{"key":"10143_CR129","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3892\/ol.2012.928","volume":"4","author":"J Zheng","year":"2012","unstructured":"Zheng, J. Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (Review). Oncol. Lett. 4, 1151\u20131157 (2012).","journal-title":"Oncol. Lett."},{"key":"10143_CR130","doi-asserted-by":"crossref","unstructured":"DeBerardinis, R. J. & Chandel, N. S. Fundamentals of cancer metabolism. Sci. Adv. 2, e1600200 (2016).","DOI":"10.1126\/sciadv.1600200"},{"key":"10143_CR131","doi-asserted-by":"crossref","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"10143_CR132","doi-asserted-by":"crossref","unstructured":"Wei, Y., Zhang, B., Bie, Q. & He, B. Metabolic regulation in the senescence process of stem cells. Stem Cells Transl. Med. 14, szaf041 (2025).","DOI":"10.1093\/stcltm\/szaf041"},{"key":"10143_CR133","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1158\/0008-5472.CAN-24-1204","volume":"85","author":"S Tau","year":"2025","unstructured":"Tau, S. et al. Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy\u2013tolerant persister cells in ER+ breast cancer. Cancer Res. 85, 1145\u20131161 (2025).","journal-title":"Cancer Res."},{"key":"10143_CR134","doi-asserted-by":"crossref","unstructured":"Pendleton, K. E., Wang, K. & Echeverria, G. V. Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations. Front. Cell Dev. Biol. 11, 1254313 (2023).","DOI":"10.3389\/fcell.2023.1254313"},{"key":"10143_CR135","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fmicb.2014.00070","volume":"5","author":"SM Amato","year":"2014","unstructured":"Amato, S. M. et al. The role of metabolism in bacterial persistence. Front. Microbiol. 5, 70 (2014).","journal-title":"Front. Microbiol."},{"key":"10143_CR136","doi-asserted-by":"publisher","unstructured":"Keoh, L. Q., Chiu, C.-F. & Ramasamy, T. S. Metabolic plasticity and cancer stem cell metabolism: exploring the glycolysis-oxphos switch as a mechanism for resistance and tumorigenesis. Stem Cell Rev. Rep. https:\/\/doi.org\/10.1007\/s12015-025-10956-y (2025).","DOI":"10.1007\/s12015-025-10956-y"}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10143-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10143-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10143-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T21:02:46Z","timestamp":1777410166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-10143-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":136,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10143"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-10143-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"587"}}